Ledipasvir-factory

Min.Order / FOB Price:Get Latest Price

0 Metric Ton	Negotiable

0 Metric Ton

Negotiable

Min.Order :0 Metric Ton
Purity: 99%
Payment Terms : L/C,T/T,Other

Keywords

Ledipasvir-factory 1256388-51-8 Ledipasvir API

Quick Details

Appearance:white powder
Application:Hepatitis c virus (HCV) API CAS NO.1256388-51-8
PackAge:
ProductionCapacity:|Metric Ton|Day
Storage:
Transportation:

Superiority:

GS 588;GS5885;GS 5885;GS-5885;Ledipasvir;Leidipawei;gs-5885/gs5885;HY-15602 (GS-5885;GS-5885/Ledipasvir;Ledipasvir / GS 5885

CBNumber:

CB52666650

factory

Details:

Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.^[1] After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C.^[2]^[3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.

Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analog inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1.^[4]^[5] The sofosbuvir/ledipasvir coformulation is being tested with and without ribavirin. In February 2014 Gilead has filed for United States Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment, without interferon and ribavirin.^[6]

On October 10, 2014 the FDA approved the combination product ledipasvir/sofosbuvir called Harvoni.^[7]

View All

Visit Store